KALV vs. TVTX, ALT, OCS, VERV, STTK, LRMR, ANL, CMPS, ABUS, and ATXS
Should you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Travere Therapeutics (TVTX), Altimmune (ALT), Oculis (OCS), Verve Therapeutics (VERV), Shattuck Labs (STTK), Larimar Therapeutics (LRMR), Adlai Nortye (ANL), COMPASS Pathways (CMPS), Arbutus Biopharma (ABUS), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical preparations" industry.
Travere Therapeutics (NASDAQ:TVTX) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, community ranking, dividends and media sentiment.
KalVista Pharmaceuticals has lower revenue, but higher earnings than Travere Therapeutics. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.
KalVista Pharmaceuticals received 276 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 73.93% of users gave KalVista Pharmaceuticals an outperform vote while only 48.62% of users gave Travere Therapeutics an outperform vote.
Travere Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
KalVista Pharmaceuticals has a net margin of 0.00% compared to KalVista Pharmaceuticals' net margin of -87.94%. Travere Therapeutics' return on equity of -86.06% beat KalVista Pharmaceuticals' return on equity.
In the previous week, Travere Therapeutics had 10 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 13 mentions for Travere Therapeutics and 3 mentions for KalVista Pharmaceuticals. Travere Therapeutics' average media sentiment score of 0.62 beat KalVista Pharmaceuticals' score of 0.27 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media.
Travere Therapeutics presently has a consensus price target of $16.69, suggesting a potential upside of 149.51%. KalVista Pharmaceuticals has a consensus price target of $25.00, suggesting a potential upside of 107.13%. Given KalVista Pharmaceuticals' higher possible upside, equities analysts plainly believe Travere Therapeutics is more favorable than KalVista Pharmaceuticals.
Summary
KalVista Pharmaceuticals beats Travere Therapeutics on 8 of the 15 factors compared between the two stocks.
Get KalVista Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KalVista Pharmaceuticals Competitors List
Related Companies and Tools
